Jinru Shia

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:293-300. 2008
  2. ncbi Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:131-8. 2013
  3. ncbi TNM staging of colorectal carcinoma: issues and caveats
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Diagn Pathol 29:142-53. 2012
  4. ncbi An update on tumors of the anal canal
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1601-11. 2010
  5. ncbi Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 35:447-54. 2011
  6. ncbi Metastatic epithelioid gastrointestinal stromal tumor: yet another tumor with anemone cell features
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 27:95-100. 2003
  7. ncbi Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 39:498-505. 2008
  8. ncbi Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:96-104. 2005
  9. ncbi Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience
    Patrick S Wolf
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 216:41-9. 2013
  10. ncbi Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone
    Aviram Nissan
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4078-84. 2006

Detail Information

Publications102 found, 100 shown here

  1. ncbi Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:293-300. 2008
    ....
  2. ncbi Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:131-8. 2013
    ....
  3. ncbi TNM staging of colorectal carcinoma: issues and caveats
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Diagn Pathol 29:142-53. 2012
    ..The article also provides a brief discussion about some of the major adjunct histopathologic prognostic factors, such as medullary-type histology and tumor differentiation...
  4. ncbi An update on tumors of the anal canal
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1601-11. 2010
    ..The anal canal possesses complex anatomy and histology and gives rise to a variety of tumor types. Challenging issues remain with regard to both the pathologic diagnosis and the clinical management of these tumors...
  5. ncbi Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 35:447-54. 2011
    ..However, whether biopsy samples can be reliably used for mismatch repair protein detection remains to be determined...
  6. ncbi Metastatic epithelioid gastrointestinal stromal tumor: yet another tumor with anemone cell features
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 27:95-100. 2003
    ....
  7. ncbi Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 39:498-505. 2008
    ..The significance of such an association as well as the prognostic value of FRalpha expression deserves further exploration...
  8. ncbi Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:96-104. 2005
    ....
  9. ncbi Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience
    Patrick S Wolf
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 216:41-9. 2013
    ..This study investigates the effect of preoperative chemotherapy for CRCLM on nontumoral liver histology and perioperative outcomes in a contemporary cohort...
  10. ncbi Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone
    Aviram Nissan
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4078-84. 2006
    ..CONCLUSION Patients with T2-3, N0 rectal cancers and either lymphovascular invasion or elevated CEA levels have reduced survival and a higher incidence of PR, and should be considered for future randomized trials...
  11. ncbi Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma
    Steven C Katz
    Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg 249:617-23. 2009
    ..To determine if the degree of blood loss during resection of hepatocellular carcinoma (HCC) is predictive of recurrence and long-term survival...
  12. ncbi Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 33:1639-45. 2009
    ..Such a cost-effective approach carries significant implication, as immunohistochemistry is being widely used as first-line screening for HNPCC...
  13. ncbi Response to neoadjuvant therapy in patients with early age-of-onset rectal cancer
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Dis Colon Rectum 56:58-63. 2013
    ..The response to neoadjuvant treatment in patients ≤ 50 years of age is not known. Factors affecting the response to neoadjuvant therapy in this age group have not been evaluated...
  14. ncbi Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis
    Tobias Leibold
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:2783-9. 2011
    ..We prospectively evaluated tumor response with (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) early in the course of preoperative CRT...
  15. ncbi Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy
    Tobias Leibold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 1077, New York, NY 10021, USA
    J Clin Oncol 26:2106-11. 2008
    ..The aim of this study was to examine the prognostic significance of location of involved lymph nodes in rectal cancer patients after preoperative chemoradiotherapy...
  16. ncbi Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome
    George A Poultsides
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2797-804. 2012
    ..Histologically, dominant response patterns include fibrosis, necrosis and/or acellular mucin, but some of these changes can appear without previous chemotherapy and their individual correlation with outcome is unknown...
  17. ncbi Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation
    Hak Mien Quah
    Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:57-64. 2008
    ....
  18. ncbi Effects of obesity in rectal cancer surgery
    Hueylan Chern
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 211:55-60. 2010
    ..In this study, we evaluate whether higher body mass index (BMI) compromises surgical resection in patients with locally advanced, mid-to-low rectal cancer after neoadjuvant therapy, adversely affecting long-term oncologic outcomes...
  19. ncbi Squamous-cell carcinoma of the anal canal: predictors of treatment outcome
    Ramin Roohipour
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 51:147-53. 2008
    ..The incidence of anal canal squamous-cell carcinoma is increasing. Limited data exist on predictors of treatment failure. This study was designed to identify predictors for relapse/persistence after first-line therapy...
  20. ncbi Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10002, USA
    Am J Surg Pathol 27:1407-17. 2003
    ..Using a stepwise logistic regression model, a formula was generated that could be used to calculate the probability of a colorectal carcinoma being MSI-H based on morphologic features...
  21. ncbi Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Rohit Bhargava
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1857-62. 2006
    ..Either antibody may be used for immunohistochemical detection of EGFR in colorectal carcinomas. In addition, manual scoring had an excellent correlation with automated scoring...
  22. ncbi Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome
    Harvey G Moore
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-1077, New York, NY 10021, USA
    Ann Surg Oncol 11:955-61. 2004
    ..Expression of p27 in the residual rectal cancer may therefore identify patients with disease likely to be refractory to standard therapy and for whom investigational approaches should be strongly considered...
  23. ncbi Rate of residual disease after complete endoscopic resection of malignant colonic polyp
    Jean M Butte
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Dis Colon Rectum 55:122-7. 2012
    ..Following polypectomy, colectomy is performed selectively to ensure complete clearance of neoplasia...
  24. ncbi A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography
    Francesco Stipa
    Department of Surgery-Colorectal Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-1077, New York, New York 10021, USA
    Ann Surg Oncol 13:1047-53. 2006
    ..Because pCR seems to be associated with better outcome, an understanding of the factors governing the response to CMT should be pursued...
  25. ncbi Limitations of early rectal cancer nodal staging may explain failure after local excision
    Ron G Landmann
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 50:1520-5. 2007
    ..The limitations of endorectal ultrasound in accurately staging nodal disease in early rectal lesions may, in part, explain the relatively high recurrence rates seen after local excision...
  26. ncbi Squamous-cell carcinoma of the rectum: a rare but curable tumor
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Dis Colon Rectum 50:1393-400. 2007
    ..This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma...
  27. ncbi Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Hak Mien Quah
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 51:503-7. 2008
    ..The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients...
  28. ncbi FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation
    Jeannine A Ruby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Dis Colon Rectum 55:378-86. 2012
    ..At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic rectal cancer...
  29. ncbi A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma
    Clifford S Cho
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 206:281-91. 2008
    ..Numerous staging systems have been devised for purposes of risk classification; we sought to identify the optimal staging system to predict postoperative survival...
  30. ncbi Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer
    Jose G Guillem
    Department of Surgery Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:829-36; discussion 836-8. 2005
    ....
  31. ncbi Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point
    Jose G Guillem
    Colorectal Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 1077, New York, NY 10021, USA
    J Clin Oncol 23:3475-9. 2005
    ..However, because the accuracy of this approach has not been established, we conducted a prospective analysis to determine the operating surgeon's ability to assess response using DRE...
  32. ncbi Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Am J Surg Pathol 28:215-23. 2004
    ..Our results demonstrate distinct morphologic features in treated rectal carcinomas that are prognostically relevant...
  33. ncbi Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment
    Bridget N Fahy
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:1735-43. 2007
    ..Predicting rectal carcinoid behavior based exclusively on tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a pre-operative risk stratification scheme...
  34. ncbi Resection of adrenocortical carcinoma liver metastasis: is it justified?
    Sebastien Gaujoux
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2643-51. 2012
    ..Adrenocortical carcinoma (ACC) liver metastases (LM) represent a therapeutic challenge, and it is unclear whether resection is justified. This study assesses long-term outcome and prognostic factors after liver resection for metastatic ACC...
  35. ncbi Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 249:236-42. 2009
    ....
  36. ncbi Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 32:1429-43. 2008
    ..Surgical management with right hemicolectomy is recommended after appendectomy for most cases, particularly those with an adenocarcinoma component (groups B and C)...
  37. ncbi Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 35:127-34. 2011
    ....
  38. ncbi Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma
    Ippolito Modica
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 31:744-51. 2007
    ..In the future, as prognostic and therapeutic implications of MSI phenotype become better defined, it may be reasonable to perform IHC for mismatch repair proteins in large numbers of endometrial carcinomas...
  39. ncbi A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:88-93. 2007
    ....
  40. ncbi Surgical salvage of recurrent rectal cancer after transanal excision
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:1169-75. 2005
    ..This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors...
  41. ncbi Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study
    Peirong Ding
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 256:111-6. 2012
    ..To characterize patterns of recurrence in locally advanced rectal cancer treated with combined modality therapy (CMT): neoadjuvant chemoradiation + total mesorectal excision + adjuvant chemotherapy...
  42. ncbi Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy
    Anand Govindarajan
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4568-73. 2011
    ..We sought to examine the feasibility and clinical significance of current guidelines on nodal assessment in patients with rectal cancer (RC) treated with neoadjuvant radiation...
  43. ncbi Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma
    Kui-Hin Liau
    Hepatobiliary Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1948-55. 2005
    ..Minimizing intraoperative blood loss appears to be critical for favorable long-term outcome in patients with large HCC...
  44. ncbi Liver angiomyolipomas: a clinical, radiologic, and pathologic analysis of 22 patients from a single center
    Jean M Butte
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Surgery 150:557-67. 2011
    ..The spectrum of presentation, imaging and histologic features, and outcomes were analyzed in all patients treated at Memorial Sloan-Kettering Cancer Center...
  45. ncbi Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy
    Anne Y Lin
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Colorectal Dis 23:243-9. 2008
    ..The aim of this study was to identify pretreatment factors associated with poor tumor response to neoadjuvant chemoradiation...
  46. ncbi Long-term survival after transanal excision of T1 rectal cancer
    Garrett M Nash
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Dis Colon Rectum 52:577-82. 2009
    ..However, the impact of transanal excision on cancer mortality has not been adequately studied. The purpose of this study was to compare oncologic outcomes of transanal excision with those of radical resection...
  47. ncbi A predictive model for lymph node yield in colon cancer resection specimens
    Garrett M Nash
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg 253:318-22. 2011
    ..To develop a predictive model of lymph node yield in a series of colon cancer resection specimens with detailed anatomic and surgical technique data...
  48. ncbi Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:560-5. 2007
    ..This study summarizes our initial experience with prospective, single-amplicon (mutation-specific) A636P testing in Ashkenazi Jewish patients at risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC)...
  49. ncbi Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:719-31. 2008
    ..These tumors are clinically aggressive. Prospective studies using defined diagnostic criteria are needed to determine their biologic characteristics and optimal management...
  50. ncbi DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors
    Yong H Wen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 36:1700-8. 2012
    ....
  51. ncbi Whole-mount pathologic analysis of rectal cancer following neoadjuvant therapy: implications of margin status on long-term oncologic outcome
    James J Mezhir
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 256:274-9. 2012
    ..We set out to determine the long-term oncologic impact of resection margins in patients with locally advanced rectal cancer using a comprehensive pathologic whole-mount section analysis...
  52. ncbi Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1221-8. 2011
    ..The prognostic value of FRα expression and the utility of FRα-targeted therapies in stage-IV colorectal cancer patients deserve further exploration...
  53. ncbi Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1350-6. 2005
    ..Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximab-based therapy...
  54. ncbi Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Virchows Arch 447:828-34. 2005
    ..Our study emphasizes the need for better attention to histologic subtypes, particularly in the context of prognostically or therapeutically oriented investigations of this lethal disease...
  55. ncbi Individualized prediction of colon cancer recurrence using a nomogram
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:380-5. 2008
    ..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
  56. ncbi Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis
    Patrick L Wagner
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Dis Colon Rectum 55:407-15. 2012
    ..At our institution, patients undergoing complete cytoreduction in this setting typically receive multiple cycles of early postoperative intraperitoneal chemotherapy...
  57. ncbi Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay
    Iyare Esemuede
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:3370-8. 2010
    ..However, the optimal assay for MSI status is unknown. We have evaluated a simplified 3-marker assay for MSI and compared it with the 5-marker (NCI) assay to see if technical variations in MSI testing are important...
  58. ncbi Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance
    Anne Lin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 38:850-6. 2007
    ..Further investigation on interaction between AMACR and other known colorectal cancer development pathways may provide new insights on colorectal carcinogenesis...
  59. ncbi Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma
    Austin Duffy
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 7:140-3. 2008
    ..He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment. The literature regarding pCR with chemotherapy in CRC and the implications for further management is discussed herein...
  60. ncbi The role of abdominoperineal resection as surgical therapy for anorectal melanoma
    Jen Jen Yeh
    Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:1012-7. 2006
    ..Therefore, LE of the primary tumor is recommended when technically feasible. The presence of PNI is an important prognostic factor and should be considered in future clinical trials...
  61. ncbi Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis
    Austin Duffy
    Deparment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Colorectal Cancer 7:402-5. 2008
    ..Platinum-based chemotherapy resulted in a divergent pathologic response as assessed after colectomy. The diagnosis and classification of mixed endocrine-exocrine tumors of the colon are discussed, along with treatment considerations...
  62. ncbi Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...
  63. ncbi High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy
    Kai A Bickenbach
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    HPB (Oxford) 13:865-8. 2011
    ..A total of 750,000 cholecystectomies are performed annually in the USA. No data exist on patients with microscopic high-grade dysplasia at the cystic duct margin and the associated incidence of cholangiocarcinoma...
  64. ncbi Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis
    Axel Hoos
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3841-9. 2002
    ..However, down-regulation of p27 appears to be associated with a trend toward reduced DFS and DSS, which suggests further investigation of other p27-related pathways potentially relevant for metastatic disease...
  65. ncbi Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment
    Bridget N Fahy
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:396-404. 2007
    ..Predicting rectal carcinoid behavior exclusively on the basis of tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a preoperative risk stratification scheme...
  66. ncbi Feasibility of ex vivo FDG PET of the colon
    Marc J Gollub
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10023, USA
    Radiology 252:232-9. 2009
    ....
  67. ncbi Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy
    Maeve A Lowery
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1714-20. 2011
    ..We present a series of 40 consecutive cases of ACC of the pancreas treated at Memorial Sloan-Kettering Cancer Center, with an emphasis on evaluation of activity of new therapeutic agents...
  68. ncbi DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases
    Narasimhan P Agaram
    Dept of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Am J Clin Pathol 133:772-80. 2010
    ..Typical MSI-high histologic features of CRC, such as increased TIL counts, seem to have similar yet subtly different implications in ampullary carcinoma...
  69. ncbi Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Diane Lauren Reidy
    Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
    J Clin Oncol 28:4240-6. 2010
    ....
  70. ncbi KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:572-8. 2010
    ..To examine more directly whether KRAS mutations are associated with accelerated metastatic progression, we evaluated KRAS mutation as well as Ki-67 expression in patients with colorectal liver metastases not treated with cetuximab...
  71. ncbi Response of stage IV anal mucosal melanoma to chemotherapy
    Jen Jen Yeh
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 6:438-9. 2005
  72. ncbi The utility of immunohistochemical detection of DNA mismatch repair gene proteins
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY 10021, New York, USA
    Virchows Arch 445:431-41. 2004
    ....
  73. ncbi T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases
    Steven C Katz
    Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:2524-30. 2009
    ..This study examines the correlation between TIL numbers and survival following hepatic resection...
  74. ncbi Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases
    Wilbur B Bowne
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:897-909. 2005
    ..Complete resection is critical to long-term survival and is associated with a single site of recurrence, perianastomotic disease, low presalvage carcinembryonic antigen level, and absence of distant disease...
  75. ncbi Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection
    Harvey G Moore
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 47:279-86. 2004
    ....
  76. ncbi Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer
    Zhaoshi Zeng
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Exp Metastasis 21:409-17. 2004
    ..C-Met protein is expressed at levels significantly higher than adjacent mucosa in most primary adenocarcinomas of the colon. Our results support an important role for c-Met in human CRC progression and metastasis...
  77. ncbi Defining surgical indications for type I gastric carcinoid tumor
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:3154-60. 2009
    ..The management of this indolent disease is controversial. The aim of this study was to evaluate endoscopic surveillance (ES) compare with surgical resection (SR) for type I GC...
  78. ncbi MSH6 germline mutations are rare in colorectal cancer families
    Paolo Peterlongo
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 107:571-9. 2003
    ..Altogether, our results indicate that disease-causing germline mutations of MSH6 are rare in HNPCC and HNPCC-like families...
  79. ncbi Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  80. ncbi Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, U.S.A
    Am J Surg Pathol 26:216-24. 2002
    ..The estimated 5-year disease-free survival was 62%, and median disease-free survival was 69 months. The estimated 5-year relapse-free survival was 54%, and the median relapse-free survival was 63 months...
  81. ncbi A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients
    Gary Deng
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    J Ethnopharmacol 136:83-7. 2011
    ..We conducted a phase II trial of SST in hepatitis C patients who were not candidates for interferon-based therapy to determine whether this agent is worthy of further study...
  82. ncbi Scirrhous metastases to the gastrointestinal tract at CT: the malignant target sign
    Marc J Gollub
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C276F, New York, NY 10021, USA
    AJR Am J Roentgenol 192:936-40. 2009
    ..CONCLUSION: Twenty-five patients with scirrhous metastases had a malignant CT target sign. Careful observation and correlation with clinical history are required to differentiate this unique sign from a benign target sign...
  83. ncbi Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients
    Richard K G Do
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Pediatr Radiol 41:335-40. 2011
    ..FNH can be incidentally found on CT and MRI and can be misdiagnosed as liver metastasis in patients with an oncological history...
  84. ncbi HER 2/neu expression and gene amplification in colon cancer
    Daniel R Nathanson
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 105:796-802. 2003
    ..These data indicate that the primary mechanism of dysregulated HER 2/neu expression in colon cancer, as in breast cancer, is gene amplification...
  85. ncbi An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer
    Deborah Schrag
    Memorila Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:1799-802. 2005
  86. ncbi Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation
    Charles H Cha
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 238:315-21; discussion 321-3. 2003
    ..Resection should be considered the standard therapy for patients with HCC who have adequate liver reserve...
  87. ncbi Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review
    Rabih Said
    Staten Island University Hospital, New York, USA
    Eur J Gastroenterol Hepatol 22:246-52. 2010
    ..As the data confers a worse prognosis versus other pancreatic neuroendocrine tumors, the relatively favorable outcome of the two patients reported herein may reflect the impact of multiple therapeutic modalities...
  88. ncbi Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection?
    Francesco Stipa
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 11:187-91. 2004
    ....
  89. ncbi Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
    Udai S Kammula
    Surgery Branch, National Cancer Institute, Bethesda, MD, USA
    Cancer Lett 248:219-28. 2007
    ..We hypothesize that over-expression of the c-Met receptor and its ligand, hepatocyte growth factor (HGF) in the tumor microenvironment is associated with tumor progression and metastases...
  90. ncbi Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis
    Tzeela Cohen
    Department of Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    J Surg Oncol 97:416-22. 2008
    ..This study was conducted to determine survival according to the expression of molecular markers in colorectal cancer (CRC) patients of various ethnic origins...
  91. ncbi GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1
    Yu Wen
    Robert Wood Johnson Medical School and Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 12:5951-9. 2006
    ..We found that the mRNA and protein products of GROalpha are more highly expressed in neoplastic than normal colon epithelium, and we studied potential mechanisms by which GROalpha may contribute to tumor initiation or growth...
  92. ncbi Relationship of gene expression and chromosomal abnormalities in colorectal cancer
    Dafna Tsafrir
    Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel
    Cancer Res 66:2129-37. 2006
    ....
  93. ncbi Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy
    Silke Lassmann
    Institute of Pathology, University Hospital, Albert Ludwigs University Freiburg, Freiburg, Germany
    Gastroenterology 133:1831-9. 2007
    ....
  94. ncbi Lymph node metastasis in T1 adenocarcinoma of the colon and rectum
    Satoshi Okabe
    Department of Surgery, Tokyo Medical and Dental University, Tokyo, Japan
    J Gastrointest Surg 8:1032-9; discussion 1039-40. 2004
    ..In early colorectal cancers, tumor morphology is the strongest clinical predictor of metastatic behavior...
  95. ncbi Intramucosal poorly differentiated colorectal carcinoma: can it be managed conservatively?
    Jinru Shia
    Am J Surg Pathol 32:1586-8; author reply 1588-9. 2008
  96. ncbi Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Virchows Arch 449:148-58. 2006
    ..The 5-year recurrence-free survival was 27.4%. From data available at the current time, we were not able to identify prognostically significant pathologic factors...
  97. ncbi Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains
    Rohit Bhargava
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:40-7. 2005
    ..We therefore recommend the use of a small antibody panel comprising anti-CD10, anti-estrogen receptor, and anti-CD34 to distinguish endometrial stromal sarcomas from tumors with a predominant hemangiopericytomatous growth pattern...
  98. ncbi The signatures of autozygosity among patients with colorectal cancer
    Manny D Bacolod
    Department of Microbiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Res 68:2610-21. 2008
    ....
  99. ncbi Preoperative radiographic assessment of hepatic steatosis with histologic correlation
    Clifford S Cho
    Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792 7375, USA
    J Am Coll Surg 206:480-8. 2008
    ..But the accuracy of preoperative radiologic assessment of fatty liver disease remains unclear. The objective of this study was to correlate preoperative radiologic estimation with postoperative histologic measurement of steatosis...
  100. ncbi The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects
    Marco Seandel
    Clin Cancer Res 12:6203-4. 2006
  101. ncbi BLM heterozygosity and the risk of colorectal cancer
    Stephen B Gruber
    Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI 48109, USA
    Science 297:2013. 2002